Study reveals major differences between human and mouse PD-1 in cancer research

FHS
January 4, 2025
12:26 am

Since its discovery in the 1990s, “programmed cell death protein 1,” or PD-1, has been regarded as a leading target in cancer treatments.

UCB adds three more FDA approvals to label for potential blockbuster Bimzelx

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 24, 2024

We tried to quantify how harmful hospital ransomware attacks are for patients. Here’s what we found

This article is part of a partnership between First Opinion and Tradeoffs, a nonprofit news organization exploring our confusing, costly, and often counterintuitive health care system. To

November 17, 2023

Rubedo pulls in $40M Series A to advance atopic dermatitis candidate targeting aging cells

Rubedo Life Sciences is furthering its plan to treat age-related diseases by targeting senescent cells with a $40 million Series A led by Khosla Ventures

April 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.